CTRI/2019/08/020697尚未招募不适用
An open randomized controlled clinical trial to study the triphala yog in the management of galganda in comparision with thyroxine with special reference to hypothyroidism
Dr Vishala R Dodke1 个研究点 分布在 1 个国家目标入组 77 人开始时间: 2019年8月19日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 77
- 试验地点
- 1
- 主要终点
- Triphalayog more effective in management of Hypothyroidsm than Thyroxine
研究概览
简要总结
Title- an open randomised controlled clinical trail to study the triphala yog in the management of galganda in comparision with thyroxime with special refrence to hypothyroidism.
Trial group - triphala yog
Dose of triphala yog - 100ml orally
Control group - tab thyroxime
Dose of thyroxine - 50 to 100 mcg as per severity of symptoms
Assessment criteria-
Objective criteria - serum TSH, serum t3, serum t4 level, will be done before and after the trial
Subjective criteria - weight gain, amenorrhea, hoarseness of voice, loss of appetite, constipation, somnolence, dyspnoea, debility, dryness, hair loss
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- All
入选标准
- •Diagnosed patients of hypothyroidism Patients of either gender Age > 18 years to 80 years Serum ultrasensitive TSH level >5 micro iu/ml.
排除标准
- •Immunocompromised patients or patients on immunosuppresive drugs Patients suffering from life threating disease Pregnancy and lactating mother K/C/O Thyroid neoplasia, congenital hypothyroidism Progressive cause of myxoedema coma Infiltrative disorders like sarcoidosis.
结局指标
主要结局
Triphalayog more effective in management of Hypothyroidsm than Thyroxine
时间窗: once in month for three months
次要结局
- Triphalayog does not have effect in management of Hypothyroidsm(Once in a month for three months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)Respiratory Tract InfectionsTuberculosisPneumoniaNCT03545373London School of Hygiene and Tropical Medicine1,583
Unknown
2 期
Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19.Coronavirus Disease 2019 (COVID-19)NCT04395170Lifefactors Zona Franca, SAS75
已完成
3 期
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device OcclusionCatheter ObstructionVascular Access DevicesNCT01958164Boehringer Ingelheim16
Unknown
3 期
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary CancerAdvanced Biliary CancerNCT04809142Chia Tai Tianqing Pharmaceutical Group Co., Ltd.392
已完成
3 期
Eltrombopag Phase III Study In Chinese Chronic ITP PatientsPurpura, Thrombocytopenic, Idiopathic and Hepatitis CNCT01762761Novartis Pharmaceuticals155